Professor of Hematology and Medical Oncology, Pediatrics & Medicine
Winship Cancer Institute at Emory University
Emory Personalized Immunotherapy Center [EPIC]
Emory University Hospital
Dr. Galipeau is a Professor of Hematology and Medical Oncology, Pediatrics & Medicine, Emory School of Medicine and is Co-Director of the Winship Cancer Institute Tumor Immunology-Immunotherapy initiative as well as Director of the Emory Personalized Immunotherapy Center (EPIC) and has been named a Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Jacques Galipeau obtained his Medical Degree from the University of Montreal in 1988 and completed specialty training in internal medicine at the McGill-affiliated Jewish General Hospital. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology and Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children’s research hospital in Memphis Tennessee. In his 12 year career at McGill University starting in 1997, he initiated and developed a research program in cell and immunotherapy of catastrophic illnesses including cancer, immune and cardiovascular disease. The development of regenerative medicine and innovative cell-based therapies are on-going research and development interests pursued at Emory University since October 2009.
Since 1997, Dr. Galipeau has initiated and developed a research program in cell and gene therapy of catastrophic illnesses including cancer, immune and cardiovascular disease. The goal of Dr. Galipeau’s research is to continue the development of a remarkable new class of biological agents we invented: the GIFT fusokines. These are in essence fusion proteins borne of GMCSF (at the N-terminus) and interleukins (at the C-terminus) whose acquired immunobiological properties render them extremely attractive as a novel biopharmaceutical strategy to treat cancer. Dr. Galipeau’s team is studying the use of GIFT21 in vitro, in mouse models of cancer and in human cells.
As co-Director for the Tumor Immunology Immunotherapy Program within the Winship Cancer Institute, Dr. Galipeau’s mandate is to develop and implement innovative trans-disciplinary translational (bench to bedside) research in cell-based and biological therapeutics and Tumor Immunotherapy. He has benefited from continuous operational funding from the Canadian Institute for Health Research (The Canadian equivalent of NIH) since 1998. He was recently granted a Georgia Cancer Coalition Distinguished Cancer Clinician and Scientist Award. To date, he has published 96 medline-indexed, peer-reviewed papers and reviews. Of these, 30 were published in the past 2 years (20 of which he is senior/corresponding author), including an original report in Nature Medicine. In the past 5 years, he has participated in a multitude of regional, national and international peer-review committees, including serving as Scientific Officer and Chair of CIHR Cardiovascular Panel B, and most recently, he is serving as a member for a NIH/NCI P01 review panel (2009/2010). As his publication record shows, he has created a line of investigation which seeks to stimulate the immune response to cancer in a radically novel manner and he intends to continue this work at Emory. For this to occur seamlessly, Dr. Galipeau secured the collaboration of talented Emory Core Directors providing imaging (Dr. A. Marcus), vivarium (Dr D. Martin) and pathology (Dr D. Brat) core services germane to his research focus. In summary, all the components of a successful scientific program are assembled: original ideas buttressed by peer-reviewed publications, goal-driven research in a supportive environment with strong complementary expertise in a team-based approach.
View publications on PubMed